Loading…
Becton, Dickinson and Company is projected to rise to $177.10 by 2027, a +17% move from its current price of $151.94. BDX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $149.57 | $152.00 | $154.48 | +0.04% |
| Jul 14 | $148.63 | $152.07 | $155.58 | +0.08% |
| Jul 15 | $147.94 | $152.13 | $156.45 | +0.13% |
| Jul 16 | $147.36 | $152.20 | $157.19 | +0.17% |
| Jul 17 | $146.86 | $152.26 | $157.86 | +0.21% |
| Jul 18 | $146.42 | $152.32 | $158.47 | +0.25% |
| Jul 19 | $146.01 | $152.39 | $159.04 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $146.01 | $152.39 | $159.04 | +0.30% |
| Week 2 | $143.88 | $152.84 | $162.36 | +0.59% |
| Week 3 | $142.36 | $153.29 | $165.07 | +0.89% |
| Week 4 | $141.15 | $153.74 | $167.46 | +1.19% |
| Week 5 | $140.15 | $154.20 | $169.66 | +1.49% |
| Week 6 | $139.29 | $154.65 | $171.72 | +1.79% |
| Week 7 | $138.53 | $155.11 | $173.68 | +2.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BDX, or Becton, Dickinson and Company, is a healthcare company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. The portfolio spans IV and advanced peripheral catheters, central lines, infusion systems, vascular access products, surgical and safety devices, specimen collection and diagnostic assays, automation for laboratories, and a range of reagents and instruments for clinical testing.
The company also maintains collaborations to advance safety testing, such as a strategic alliance with ChemoGLO to improve hazardous drug contamination testing in health care settings. BDX was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
BDX is a healthcare stock with a broad device, instrumentation, and diagnostics footprint. It carries a market cap of $42.96B and is ranked 352 by market capitalization among listed equities. The current price sits at $155.92 per share.
The near-term price outlook shows a neutral stance for 2026, with a 2026 min of $140.71, an avg of $155.92, and a max of $211.46, and a 0% ROI. Over the longer horizon, the forecast projects continued upside with higher price levels and growing ROI across successive years, rising from 2027 onward to new highs.
A major floor 12.5% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 4.0% above — a clean break opens room to run.
A major ceiling 14.7% above — clearing it would confirm fresh momentum.
Key BDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $153.04 | Sell | $152.44 | Sell |
| MA 10 | $153.86 | Sell | $152.26 | Sell |
| MA 20 | $149.61 | Buy | $150.96 | Buy |
| MA 50 | $148.06 | Buy | $150.53 | Buy |
| MA 100 | $155.33 | Sell | $152.34 | Sell |
| MA 200 | $154.29 | Sell | $154.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.41 | Neutral |
| Stoch RSI (14) | 57.09 | Neutral |
| CCI (20) | 35.06 | Neutral |
| Williams %R (14) | -35.35 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | 5.57 | Buy |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 64.65 | Neutral |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 4.14 | Buy |
| Ultimate (7,14,28) | 54.37 | Neutral |
| Momentum (10) | 0.56 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 151.17 | Buy |
| ADX (14) | 12.82 | Neutral |
| ATR (14) | 2.39 | Info |
The 30-day technical picture is bullish, with a current RSI14 of 60 and price structure near key moving averages. The SMA50 is $148.23, and the SMA200 sits at $154.01, placing current price action around the vicinity of the longer-term trend. Immediate support is identified at $140.71 and resistance at $155.92, with the 30-day trading range spanning from $140.47 to $173.07.
The stock’s annualized volatility stands around 30%, indicating noticeable price movement within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $140.71 | $151.94 | $204.06 | 0% | Neutral | |
| $145.04 | $177.10 | $226.10 | +17% | Neutral | |
| $154.48 | $192.17 | $251.96 | +26% | Bullish | |
| $159.07 | $200.93 | $269.06 | +32% | Bullish | |
| $166.72 | $213.44 | $290.96 | +40% | Bullish | |
| $181.99 | $235.84 | $326.57 | +55% | Bullish | |
| $196.26 | $257.19 | $361.20 | +69% | Bullish | |
| $230.28 | $304.96 | $433.83 | +101% | Bullish | |
| $250.77 | $335.40 | $482.84 | +121% | Bullish | |
| $242.62 | $327.57 | $476.81 | +116% | Bullish | |
| $349.12 | $491.62 | $749.92 | +224% | Bullish | |
| $582.25 | $879.34 | $1,437.80 | +479% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $140.71 | $151.94 | $181.86 | +0.00% |
| August 2026 | $131.53 | $153.98 | $184.18 | +1.34% |
| September 2026 | $134.23 | $157.89 | $190.33 | +2.54% |
| October 2026 | $139.54 | $164.81 | $199.97 | +4.38% |
| November 2026 | $140.69 | $166.75 | $203.43 | +1.18% |
| December 2026 | $139.96 | $166.41 | $204.06 | -0.20% |
Click any year to see its month-by-month BDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BDX could reach as high as $204.06, with a base case around $151.94 and support toward $140.71 — roughly 0% from $151.94. A consolidation phase looks the most probable path here.
Expect BDX to range from $145.04 to $226.10 through 2027. The $177.10 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
The BDX price prediction for 2028 points to an average of $192.17 (low $154.48, high $251.96) — a potential gain of +26% on today's $151.94. Buyers look set to stay in control over this stretch.
In 2029, BDX is projected to trade between $159.07 and $269.06, averaging $200.93 — a potential gain of +32% from today's $151.94. That is up +5% on the projected 2028 average. Momentum favours further upside here.
Becton, Dickinson and Company's 2030 outlook centres on $213.44, within a $166.72 to $290.96 range. That is up +6% on the projected 2029 average. That marks a +40% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, BDX could reach as high as $326.57, with a base case around $235.84 and support toward $181.99 — roughly +55% from $151.94. Momentum favours further upside here.
Expect BDX to range from $196.26 to $361.20 through 2032. The $257.19 average target implies a +69% move from current prices. That is up +9% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The BDX price prediction for 2033 points to an average of $304.96 (low $230.28, high $433.83) — a potential gain of +101% on today's $151.94. Momentum favours further upside here.
In 2034, BDX is projected to trade between $250.77 and $482.84, averaging $335.40 — a potential gain of +121% from today's $151.94. That is up +10% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Becton, Dickinson and Company's 2035 outlook centres on $327.57, within a $242.62 to $476.81 range. That is -2% versus the projected 2034 average. That marks a +116% change versus current levels. Momentum favours further upside here.
By 2040, BDX could reach as high as $749.92, with a base case around $491.62 and support toward $349.12 — roughly +224% from $151.94. Buyers look set to stay in control over this stretch.
Expect BDX to range from $582.25 to $1,437.80 through 2050. The $879.34 average target implies a +479% move from current prices. That is up +79% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BDX today (≈ 6.581545 BDX) could be worth
$5,787.39
+$4,787.39 (+479%) by 2050 · US Dollar
Based on the average projected BDX price of $879.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDXwould be worth at today's price.
$1,000 invested in BDX on Jul 10, 2025 (≈ 7.166197 BDX) would be worth
$1,088.83
+$88.83 (+8.9%) today · 1.09× · US Dollar
Based on a BDX entry price of $139.54 vs. today's $151.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $158.08 | $961.16 | -3.9% |
| 1 month ago | $147.79 | $1,028.08 | +2.8% |
| 3 months ago | $154.22 | $985.22 | -1.5% |
| 6 months ago | $159.39 | $953.28 | -4.7% |
| 1 year ago | $139.54 | $1,088.83 | +8.9% |
| All time (5.0y) ago | $190.69 | $796.8 | -20.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDX forecast.
Our base-case forecast reaches $300.00 around 2033.
Implied market cap at $300.00: $82.66B
The multi-year forecast outlines a strong upward trajectory after 2026. In 2027, the avg is $183.42 with a max of $234.44 and a min of $150.10 (ROI 17.6, sentiment Neutral). By 2028, the avg rises to $196.21 (max $257.49, min $157.63, ROI 25.8, sentiment Bullish), and by 2029 the avg is $209.73 (max $281.05, min $165.95, ROI 34.5, Bullish).
The 2030 forecast shows an avg of $221.88 (min $173.23, max $302.65, ROI 42.3, Bullish), continuing to 2031 with avg $241.51 and 2032 $270.70 (ROI 54.9 and 73.6 respectively). The path grows through 2033 ($319.40 avg), 2034 ($345.14 avg), and 2035 ($341.34 avg) with bullish sentiment and rising max values. By 2040, the avg is $511.05 (max $779.80, min $362.81, ROI 227.8, Bullish) and by 2050 the avg is $923.87 (max $1,510.97, min $611.59, ROI 492.5, Bullish).
These figures describe an expanding price outlook with substantial upside potential, while noting that forecasts are estimates and not guarantees. The trajectory reflects ongoing demand for healthcare equipment and diagnostics in a challenging and evolving market environment.
Tap a question to reveal the answer.
2030 forecast shows an avg of $221.88, a min of $173.23, and a max of $302.65, with an ROI of 42.3% and a bullish sentiment.
The multi-year outlook turns bullish after 2026, with rising averages and increasing ROI—from $183.42 avg in 2027 to $923.87 avg in 2050 and a max around $1,510.97 by 2050—though 2026 is neutral with an avg of $155.92 and 0% ROI.
Yes, the forecast shows a max of $1,510.97 in 2050, indicating a potential path above $1,000 in the longer term.
For 2026, the min is $140.71, the avg is $155.92, the max is $211.46, with a neutral sentiment and 0% ROI.
The current price is $155.92 per share and the market cap is $42.96B, with a market rank of 352.
Becton, Dickinson and Company Community Discussion
0Share your Becton, Dickinson and Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.